Biosimilars

Pharmalot By Ed Silverman

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Pharmalot By Ed Silverman

Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Pharmalot By Ed Silverman

Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks

Pharmalot By Ed Silverman

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalot By Ed Silverman

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Pharmalot By Ed Silverman

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Politics By Lev Facher

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Pharmalot By Ed Silverman

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

Pharmalot By Ed Silverman

More hospital drug spending is going toward cancer immunotherapies

Pharmalot By Ed Silverman

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

First Opinion By Juliana Reed

Some bipartisan support for biosimilars is good. More would be better

First Opinion By Jessica Sagers and Peter Kolchinsky

Booker-Sanders-Harris drug affordability bureau could be brilliant

Pharmalot By Ed Silverman

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

First Opinion By Jonathan Kimball

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pharmalot By Ed Silverman

Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes

Pharmalot By Ed Silverman

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalot By Ed Silverman

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

Pharmalot By Ed Silverman

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

Pharmalot By Ed Silverman

AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.

Pharmalot By Ed Silverman

AbbVie is eager for its new psoriasis drug to be a hit, but analysts offer caveats

First Opinion By Brad Jordan

U.S. biologics and biosimilars need distinguishable names

Pharmalot By Ed Silverman

Pharmalittle: U.K. adviser complains pharma ignores antibiotics; FDA to revamp manufacturing rules

First Opinion By Carlos Sattler and Sheila Frame

Biosimilar approval and adoption in the U.S. needs to be expedited

Pharmalot By Ed Silverman

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

Pharmalot By Ed Silverman

Most Read

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

Five years on, biosimilars need support from all health care players

Watch: What is a biosimilar, exactly?

Biosimilars could disappear if the Supreme Court overturns the ACA

Large employers could have saved money if more biosimilars had been prescribed

Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions

From bench to bedside, biologics require excellence at every stage

Webinar: Will biosimilars ever realize their promise in the U.S. market?

All Coverage

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

More hospital drug spending is going toward cancer immunotherapies

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

Some bipartisan support for biosimilars is good. More would be better

Booker-Sanders-Harris drug affordability bureau could be brilliant

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.

AbbVie is eager for its new psoriasis drug to be a hit, but analysts offer caveats

U.S. biologics and biosimilars need distinguishable names

Pharmalittle: U.K. adviser complains pharma ignores antibiotics; FDA to revamp manufacturing rules

Biosimilar approval and adoption in the U.S. needs to be expedited

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument